Nineteen-ninety-three was a banner year for the demonstration of beneficial effects of interventions on outcomes in patients with diabetes and, in particular, with diabetic nephropathy. The Collaborative Study Group studying the effects of treatment with angiotensinconverting enzyme (ACE) inhibitors on the progression of diabetic nephropathy reported strongly positive results (1), hard on the heels of the publication of the results of the Diabetes Control and Complications Trial (DCCT) (2).